Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of XL184 with or without Erlotinib in Subjects with Non-Small Cell Lung Cancer (XL184-202)

Next Previous
Trial Profile

A Phase 1b/2 Study of XL184 with or without Erlotinib in Subjects with Non-Small Cell Lung Cancer (XL184-202)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Exelixis

Most Recent Events

  • 13 Jan 2026 Actual primary completion date changed from 1 Aug 2012 to 2 Aug 2012.
  • 18 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 30 Aug 2012 Planned End Date changed from 1 Jul 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top